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Systemic amyloidosis (AL) is the deposition of amyloid ﬁbrils derived from monoclonal light 
chains that are reproduced by clonal plasma cells. Without treatment, AL is fatal within 2 years, 
secondary to ﬁbril deposits in vital organs. The dis-ease course depends on halting monoclonal light chain 
production. Early assessment of haematological response, free light chain (FLC) production and 
prognostic markers [i.e. N-terminal natriuretic peptide type B (BNP)] every 3 months following induction 
therapy helps distinguish patients that are likely to have resolution of organ damage (Bird et al, 2004; 
Palladini et al, 2012). 
Historically, treatment consisted of alkylator-based therapy, with data extrapolated from response 
in multiple myeloma. High dose melphalan with haematopoietic cell rescue (high-dose therapy) is 
standard induction therapy for eligible patients (Vesole et al, 2006; Sanchorawala et al, 2007), result-ing 
in an improved median survival to 4.5 years, a haematological response of 30–70% and treatment-related 
mortality (TRM) as high as 22%. Standard dose melphalan with dexamethasone in patients ineligible for 
high dose therapy (HDT) has not shown matched long-term survival outcomes to high-dose therapy 
studies (Jaccard et al, 2007; Lebovic et al, 2008; Dietrich et al, 2010). 
2 
 
The comorbidities of patients ineligible for high-dose therapy in addition to the lack of survival 
beneﬁt of standard therapy to high-dose therapy, gives rise to the need for alter-native options. 
Wechalekar et al (2008) assessed bortezomib in the relapsed/refractory setting; 20 patients who 
progressed after at least one line of prior treatment were consented. Haematological response was seen in 
16 patients (80%) (Wechalekar et al, 2008). Four patients died during follow-up, three from progressive 
disease; median overall survival was not reached. Palladini et al (2014) matched 87 patients ineligible for 
HDT to receive melphalan, dexamethasone and bortezomib (MBDex) to 87 historic controls of melphalan 
and dexamethasone (MDex). Primary outcome was haematological response. A complete response was 
observed in 36 (42%) vs. 16 (19%) of MBDex v MDex group respectively (P = 0.002), and overall 
response was 69% vs. 51%; there was no difference in overall survival. 
We conducted a retrospective, single institution evaluation of 68 patients with AL, comparing 
high dose melphalan with autologous haematopoietic cell rescue to non-intensive therapy. Patients aged 
over 18 years diagnosed with systemic AL amyloidosis between January 1987 and February 2014 were 
evaluated. Patients were stratiﬁed based on receipt of high dose melphalan with cell rescue. Those that 
received non-intensive therapy were treated with either alkylator- or bortezomib-based regimens. Patients 
were not included if they did not receive systemic therapy for AL or had a concomitant malignancy. 
Approval was obtained through the Indiana University Institutional Review Board. 
Initial data collected for each patient consisted of age at diagnosis, gender, the number and type 
of organs involved. In patients with cardiac involvement, baseline mean BNP and per cent of troponin 
above normal value (0.035) were evaluated. Baseline involved FLC, time to progression and survival 
data, which were collected in all patients. 
The primary objective of this study was to determine the disease-free survival (DFS) of HDT to 
non-intensive dose therapy. Nominal data was analysed with a chi-squared or Fishers exact tests; 
continuous data was evaluated by Stu-dent’s t-test and DFS via log rank. All statistics were con-ducted 
through SPSS version 22 (SPSS, Chicago, IL, USA). 
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Sixty-eight patients met the inclusion criteria. Forty-three underwent HDT with stem cell rescue 
and 25 received non-intensive dose therapy. Mean age was 65 (range: 37–73) years for those receiving 
HDT and 55 (range: 49–82 years) for those who received non-intensive therapy (P < 0.001). Renal 
involvement was the primary organ involved in a majority of patients in both groups (Table I). Most 
patients in both groups had one involved organ: 83.7% in high-dose and 76% in non-intensive dose. 
Baseline involved FLC and tro-ponin, and were well matched between the two groups. The baseline mean 
BNP was elevated in the non-intensive dose group (643 pg/ml) compared to the high-dose group (167 
pg/ml) (P = 0.003). 
The majority of patients in the non-intensive therapy group received intravenous bortezomib 
without an alkylating agent for induction therapy (76%); median number of cycles was 4 (range 1–16). 
Other regimens included: cyclophosphamide plus bortezomib (8%), melphalan and prednisone (MP; 8%) 
and other (8%). Seven per cent of patients received some type of induction therapy prior to HDT. 
Median DFS was 53 months for patients receiving high dose melphalan and 59 months for those 
receiving non-intensive dose therapy (P = 0.86) (Fig 1). DFS of HDT com-pared to bortezomib-only 
patients was also not statistically signiﬁcant, 60 months vs. 51 months (P = 0.477). 
Previous studies evaluating non-intensive dose therapy in patients ineligible for HDT and 
haematopoietic cell rescue have not matched outcomes seen with HDT, leaving uncertainty as to the 
optimal induction regimen. Success with bortezomib has been reported in the relapsed setting and those 
failing to achieve a complete response following HDT. Bortezomib as an induction agent for patients 
ineligible for HDT is previously unknown. 
This study evaluated DFS of high-dose compared to non-intensive dose therapy in patients with 
AL. The majority of patients who received non-intensive dose therapy were ineligible for high-dose 
therapy. Unlike previously published experience (Wechalekar et al, 2008; Palladini et al, 2014), the 
majority of our non-intensive therapy patients received a short course of bortezomib-based therapy due to 
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the rapid achievement of haematological remission. DFS was not different despite an increased number of 
patients with cardiac AL in the non-intensive group. The results of this study suggest that bortezomib-
based therapy may provide an alternative induction therapy for patients ineligible for HDT, speciﬁcally 
those with underlying cardiac involvement. However, this is a retrospective study spanning many 
decades; only a prospective randomized controlled trial comparing high-dose and bortezomib induction 
regimens can accurately assess DFS. 
In conclusion, patients with amyloidosis who are unable to pursue high dose melphalan and 
autologous haematopoietic cell transplant due to organ impairment, induction with a bortezomib-based 
regimen can lead to a sustained haematological remission and may provide sustained DFS. 
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Table 1. Amyloid according to the organ involved 
Organ High-dose, n (%) (N = 43) Standard dose, n (%) (N = 25) 
Renal 32 (76·7) 12 (48) 
Gastrointestinal 2 (4·7) (0) 
Hepatic 3 (7) 1 (4) 
Cardiac 3 (7) 10 (40) 
Other 3 (7) 2 (8) 
 
 
 
Figure 1. Disease-free survival. 
 
